Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FB704A in Adults With Severe Asthma
NCT05018299Phase 2Completed
- Sponsor
- Oneness Biotech Co., Ltd.
- Start
- Sep 2021
- Primary completion
- May 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of FB 704A in severe asthma, sponsored by Oneness Biotech Co., Ltd.. Started Sep 2021; status: completed.
02
Drugs
FB 704A
03
Conditions
severe asthma
Beyond the preview
Go deeper on NCT05018299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05018299.